{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-266990","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.012233+00:00","generated_at":"2026-06-09T04:27:38.075070+00:00","sec_items":["1.01","5.03","3.02","2.01","4.01","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aileron acquires Lung Therapeutics in stock deal, raises $18M via PIPE, appoints new COO","bullets":["Acquired Lung Therapeutics for 344,566 shares of common stock and 20,140 shares of Series X Preferred; post-merger shares outstanding ~4.89M.","Raised ~$18M in private placement with Bios Partners, Nantahala Capital, and others; includes Series X Preferred and warrants exercisable at $4.89/share.","Dismissed PricewaterhouseCoopers as auditor effective upon merger close; PwC had included a going concern paragraph in prior reports.","Appointed Brian Windsor, former Lung CEO, as President and COO; elected William Fairey and Alan Musso to the board.","Jeffrey Bailey, Jodie Morrison, and William McKee resigned from the board; Josef von Rickenbach named chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-266990","json":"https://secwatch.observer/filing/0001193125-23-266990.json","markdown":"https://secwatch.observer/filing/0001193125-23-266990.md","text":"https://secwatch.observer/filing/0001193125-23-266990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/d571974d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:27:38.075070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d36a91a24e19ab07df9bef38bea12b4c9e07dd1","claim":"Rein Therapeutics, Inc. dismissed PricewaterhouseCoopers LLP as its auditor.","evidence_excerpt":"Aileron dismissed its independent registered public accounting firm, PricewaterhouseCoopers LLP (\"PwC\"), effective immediately upon the closing of the Merger.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"PricewaterhouseCoopers LLP"}],"fact_type":"auditor_change"},{"claim_id":"36504f002c","claim":"Brian Windsor was appointed as President and Chief Operating Officer at Rein Therapeutics, Inc..","evidence_excerpt":"On October 30, 2023, the Board approved the appointment of Brian Windsor, Ph.D., age 57, to President and Chief Operating Officer of Aileron, effective as of the consummation of the Merger.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"416310628a","claim":"Josef H. von Rickenbach was appointed as Chairman of the Board at Rein Therapeutics, Inc..","evidence_excerpt":"Following Mr. Bailey's resignation, Josef H. von Rickenbach will serve as the Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"5181ee63bb","claim":"Jodie P. Morrison resigned as Director at Rein Therapeutics, Inc..","evidence_excerpt":"On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6c2b4e6574","claim":"William T. McKee resigned as Director at Rein Therapeutics, Inc..","evidence_excerpt":"On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e0f2fbfdd4","claim":"Jeffrey A. Bailey resigned as Chairman of the Board at Rein Therapeutics, Inc..","evidence_excerpt":"On October 31, 2023, immediately prior to the Effective Time, Jeffrey A. Bailey, Chairman of the Board, Jodie P. Morrison and William T. McKee resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"ea8bad39370a1a6db8395b589c7eb42105675fa7","claim":"Rein Therapeutics, Inc.: Filed Certificate of Designation for Series X Non-Voting Convertible Preferred Stock (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023, Aileron filed a Certificate of Designation of Preferences, Rights and Limitations of the Series X Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Merger and the Financing referenced in Item 1.01 above.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"governance_change"},{"claim_id":"bc615d52f4f602940f7aac655fcdf28998b3f807","claim":"Rein Therapeutics, Inc. completed an acquisition involving Lung Therapeutics, Inc. (closed 2023-10-31).","evidence_excerpt":"On October 31, 2023, Aileron completed its acquisition of Lung.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Lung Therapeutics, Inc."},{"label":"Closing","value":"2023-10-31"}],"fact_type":"ma_transaction"},{"claim_id":"962f4696506005682f495eb1f8e4c502ab980d1b","claim":"Rein Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $18.0 million (effective 2023-10-31).","evidence_excerpt":"Immediately following the closing of the Merger, on October 31, 2023, Aileron entered into a Stock and Warrant Purchase Agreement (the “ Purchase Agreement ”) with a group of accredited investors (the “ Investors ”) led by Bios Partners, the majority shareholder of Lung prior to the closing of the Merger, and including Nantahala Capital, as well as additional undisclosed investors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $18.0 million"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"material_agreement"},{"claim_id":"b14d6aad148be8674552edfc6ed1779a379b871e","claim":"Rein Therapeutics, Inc. entered into Merger Agreement with Lung.","evidence_excerpt":"Pursuant to the Merger Agreement, Aileron has agreed to hold a stockholders’ meeting no later than 120 days after the date on which the closing of the Merger occurs","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Lung"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}